Database : HANSEN Search on : ENSAIOS CLINICOS [Subject descriptor] References found : 20 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 1

1 / 20

HANSEN

select to print

Id: 13728 Author: DeRossi, Scott S; Hersh, Elliot V Title: Antibiotics and oral contraceptives ..- Source: s.l; s.n; 2002. 7 p. ilus, graf. Abstract: With the exception of rifampin-like drugs, there is a lack of scientific evidence supporting the ability of commonly prescribed antibiotics, including all those routinely employed in outpatient dentistry, to either reduce blood levels and/or the effectiveness of oral contraceptives. To date, all clinical trials studying the effects of concomitant antibiotic therapy (with the exception of rifampin and rifabutin) have failed to demonstrate an interaction. Like all drugs, oral contraceptives are not 100 per cent effective with the failure rate in the typical United States population reported to be as high as 3 per cent. It is thus possible that the case reports of unintended pregnancies during antibiotic therapy may simply represent the normal failure rate of these drugs. Considering that both drug classes are prescribed frequently to women of childbearing potential, one would expect a much higher rate of oral contraceptive failure in this group of patients if a true drug:drug interaction existed. On the other hand, if the interaction does exist but is a relatively rare event, occurring in, say, 1 in 5000 women, clinical studies such as those described in this article would not detect the interaction. The pharmacokinetic studies of simultaneous antibiotic and oral contraceptive ingestion, and the retrospective studies of pregnancy rates among oral contraceptive users exposed to antibiotics, all suffer from one potential common weakness, i.e., their relatively small sample size. Sample sizes in the pharmacokinetic trials ranged from 7 to 24 participants, whereas the largest retrospective study of pregnancy rates still evaluated less than 800 total contraceptive users. Still, the incidence of such a rare interaction would not differ from the accepted normal failure rate of oral contraceptive therapy. The medico-legal ramifications of what looks like at best a rare interaction remains somewhat "murky." On one hand, we have medico-legal experts advising the profession to exercise caution and warn all oral contraceptive users of a potential reduction in efficacy during antibiotic therapy. These opinions are not evidence-based and rely heavily on one or two legal proceedings that cannot even be substantiated. On the other hand, there is one recently published legal proceeding in which the outcome was in favor of the oral surgeon. There is clearly...(AU). Descriptors: VIES (EPIDEMIOLOGIA) DISPONIBILIDADE BIOLOGICA ANTIBIOTICOS/farmacocin ANTIBIOTICOS/uso terap ESTUDOS RETROSPECTIVOS ABSORCAO INTESTINAL/ef drogas RIFABUTINA/uso terap RIFAMPINA/uso terap ANTICONCEPCIONAIS ORAIS/antag ANTICONCEPCIONAIS ORAIS/farmacocin ANTICONCEPCIONAIS ORAIS/uso terap - INTERACOES DE MEDICAMENTOS  ENSAIOS CLINICOS  JURISPRUDÊNCIA  TAMANHO DA AMOSTRA Limits: HUMANO FEMININO GRAVIDEZ Electronic Medium: http://www.ilsl.br Location: BR191.1; 09018/s

2 / 20

HANSEN

select to print

Id: 13470 Author: Brasil, Juviano; Opromolla, Diltor Vladimir Araújo; Souza-Freitas, José Alberto de; Fleury, Raul Negrão Title: Incidência de alteraçoes patológicas da mucosa bucal em pacientes portadores de hanseníase virchowiana Pathological alterations in oral mucosa of lepromatous patients- Source: s.l; s.n; Jan.-Jun. 1974. 16 p. ilus, tab. Abstract: One hundred and fifty lepromatous patients of both sexes, with active lesions, were selected for this trough clinica, bacilloscopic and histopathological examinations. Two kinds of lesions were found: active and residual. Specific active were described as maculae, infiltrations, papules, nodules and plaques, with were most frequently found, in decreasing order, in uvula, solt and hard palate, and lips. Lesions presenting positive baciloscopy, even with an apparently normal mucosa, were always considered as active. Residual lesions were destrucution, atrophy and retraction of uvula, scars and nasopalatine perforation, more frequent in those patients with longer duration of the disease.(AU). Descriptors: PATOLOGIA BUCAL HANSENIASE ENSAIOS CLINICOS MUCOSA BUCAL/patol Limits: HUMANO ADULTO RESUMO EM INGLES Electronic Medium: http://www.ilsl.br Location: BR191.1; 01541/s

3 / 20

HANSEN

select to print

Id: 13461 Author: Waters, M. F; Rees, R. J; Pearson, J. M; Laing, A. B; Helmy, H. S; Gelber, R. H Title: Rifampicin for lepromatous leprosy: nine years' experience ..- Source: s.l; s.n; January 21, 1978. 4 p. tab. Abstract: Over 100 patients with lepromatous leprosy were treated with rifampicin in a series of pilot, uncontrolled, and controlled trials in 1968-77. The rapid bactericidal effect of rifampicin on Mycobacterium leprae was confirmed. Clinical improvement became apparent sometimes as early as 14 days after the start of treatment. Nevertheless, a few persisting viable M leprae were detected as long as five years after the start of treatment with rifampicin either by itself or in combination with the bacteriostatic drug thiambutosine. Treatment with rifampicin and dapsone for six months reduced the number of persisting leprosy bacteria more than treatment with dapsone alone. Although rifampicin proved more effective than dapsone, it is unlikely that used by itself if can significantly shorten the length of treatment in lepromatous leprosy. Therefore initial intensive combined treatment with two or more bactericidal drugs (including rifampicin) warrants further investigation in both untreated leprosy and lepromatous leprosy resistant to dapsone.(AU). Descriptors: MYCOBACTERIUM LEPRAE/ef drogas HANSENIASE/quimioter ENSAIOS CLINICOS COMBINACAO DE MEDICAMENTOS DAPSONA/uso terap FENILTIOUREIA/analog FENILTIOUREIA/uso terap RIFAMPINA/admin RIFAMPINA/farmacol RIFAMPINA/uso terap Limits: HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 01449/s

4 / 20

HANSEN

select to print

Id: 13369 Author: Lwin, Kyaw; Sundaresan, T; Gyi, Mg Mg; Bechelli, L. M; Tamondong, C; Garbajosa, P. Gallego; Sansarricq, H; Noordeen SK Title: BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma ..- Source: s.l; s.n; 1985. 10 p. mapas, tab, graf. Abstract: The value of BCG vaccination in preventing leprosy among children was studied in an area of high leprosy endemicity in Burma through a controlled trial; one group of 13066 children received BCG and another group of 13176 served as controls. The overall protective effect of BCG, which was only about 20% over the 14-year period, was found to vary with the batch of vaccine, as well as age, sex, and contacts status the children. The protective effect of BCG against the lepromatous type of leprosy could not be measured because of the low incidence. Protection was observed throught the fourteen years of the study except for the firts year. The results are compared with those of three other major BCG trials in leprosy. The trial has shown that BCG provides only a very modest level of protection and that BCG vaccination is not likely to be an important solution for leprosy control.(AU). Descriptors: VACINA BCG ENSAIOS CLINICOS DEMOGRAFIA SEGUIMENTOS HANSENIASE/epidemiol HANSENIASE/prev MIANMA Limits: ESTUDO COMPARATIVO HUMANO RECÉM-NASCIDO LACTENTE PRÉ-ESCOLAR CRIANÇA ADOLESCENTE Electronic Medium: http://www.ilsl.br Location: BR191.1; 01802/s

5 / 20

HANSEN

select to print

Id: 13356 Author: Shepard, Charles C; Levy, Louis; Fasal, Paul Title: Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae ..- Source: s.l; s.n; nov. 1974. 5 p. tab, graf. Abstract: The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients lesions. In a trial of rifampin in a dosage of 600mg daily, the bacterial viability feel to undectable levels in the first specimen taken after the start of theraphy (at 3-4 days in 4 patients, 7-8 days in 9, and 4 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3-5 days in all 14 patients).(AU). Descriptors: FATORES DE TEMPO HANSENIASE/quimioter MYCOBACTERIUM LEPRAE/ef drogas DAPSONA/admin DAPSONA/farmacol ENSAIOS CLINICOS RELACAO DOSE-RESPOSTA A DROGA BIOPSIA RIFAMPINA/admin RIFAMPINA/farmacol Limits: HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 01966/s

6 / 20

HANSEN

select to print

Id: 13300 Author: Anand, L. C; Tiwari, V. D; Rathore, B. S; Singh, Onkar Title: Clinical trial with CIBA 1906 in lepromatous leprosy ..- Source: s.l; s.n; apr. 1981. 7 p. tab. Abstract: Drug trial with CIBA 1906 was conducted in 50 cases of lepromatous leprosy who were intolerant to dapsone therapy. Drug was tolerated well and lepra reactions were infrequent and mild. Clinical improvement was seen in 72% cases whereas no appreciable change was detected in 28% cases. An average reduction of 0.4 in BI was detected in 62% cases, while remaining cases did not show any reduction in BI. No significant side effects were encountered during the study. Antibacterial activity of CIBA 1906 was not found superior to dapsone.(AU). Descriptors: HANSENOSTATICOS/uso terap ENSAIOS CLINICOS HANSENIASE/quimioter FENILTIOUREIA/analog FENILTIOUREIA/ef adv FENILTIOUREIA/uso terap Limits: HUMANO MASCULINO ADULTO Electronic Medium: http://www.ilsl.br Location: BR191.1; 00694/s

7 / 20

HANSEN

select to print

Id: 13241 Author: Aronne Benach, M. T; Naranjo Cascante, G Title: Estudio de biodisponibilidad en dos preparaciones distintas de rifampicina Bioavailability of 2 different rifampicin preparations- Source: s.l; s.n; October 15, 1980. 4 p. tab, graf. Abstract: Blood levels of two different preparations of Rifampicin were determined after a standard dose of 600mg. Three hours later, blood concentrations showed no statistical differences. Six hours later the levels were statiscally significant well above the minimum inhibitory levels for Mycobacterium Tuberculosis. For practical purposes it may be said that no diference in th bioavailability existis between the two drugs studied...(AU). Descriptors: ABSORCAO INTESTINAL FATORES DE TEMPO DISPONIBILIDADE BIOLOGICA ENSAIOS CLINICOS AVALIACAO DE MEDICAMENTOS RIFAMPINA/sangue RIFAMPINA/metab RIFAMPINA/urina Limits: HUMANO MASCULINO FEMININO ADULTO MEIA-IDADE ADOLESCENTE RESUMO EM INGLES Electronic Medium: http://www.ilsl.br Location: BR191.1; 00679/s

8 / 20

HANSEN

select to print

Id: 11824 Author: Mujagic, Hamza; Chabner, Bruce A; Mujagic, Zlata Title: Mechanisms of action and potential therapeutic uses of thalidomide ..- Source: s.l; s.n; 2002. 12 p. ilus, tab. Descriptors: ENSAIOS CLINICOS MIELOMA MULTIPLO MIELOMA MULTIPLO NEOPLASIAS NEOPLASIAS SENSIBILIDADE E ESPECIFICIDADE TALIDOMIDA TALIDOMIDA TALIDOMIDA Location: BR191.1; 08562/s

9 / 20

HANSEN

select to print

Id: 11696 Author: Smith, C. M; Smith, W. C. S Title: Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis ..- Source: s.l; s.n; 2000. 6 p. tab. Descriptors: HANSENIASE HANSENIASE LEPROSTATICOS LEPROSTATICOS ACEDAPSONA ENSAIOS CLINICOS ANALISE CUSTO-BENEFICIO DAPSONA RIFAMPINA FATORES DE RISCO Location: BR191.1; 08489/s

10 / 20

HANSEN

select to print

Id: 11644 Author: Mujagic, Hamza; Chabner, Bruce A; Mujagic, Zlata Title: Mechanisms of action and potential therapeutic uses of thalidomide ..- Source: s.l; s.n; 2002. 12 p. tab. Descriptors: TALIDOMIDA TALIDOMIDA TALIDOMIDA ENSAIOS CLINICOS MIELOMA MULTIPLO MIELOMA MULTIPLO NEOPLASIAS NEOPLASIAS DEFEITOS DO TUBO NEURAL DEFEITOS DO TUBO NEURAL SENSIBILIDADE E ESPECIFICIDADE RELAÇAO ESTRUTURA-ATIVIDADE RESULTADO DE TRATAMENTO Location: BR191.1; 08505/s

11 / 20

HANSEN

select to print

Id: 11290 Author: Nath, Indira Title: A vaccine for leprosy ..- Source: s.l; s.n; 1998. 3 p. ilus, tab. Descriptors: VACINAS BACTERIANAS ENSAIOS CLINICOS REAÇOES CRUZADAS INDIA HANSENIASE MYCOBACTERIUM VACINAÇAO Location: BR191.1; 07229/s

12 / 20

HANSEN

select to print

Id: 11028 Author: Talwar, G. P Title: An Immunotherapeutic vaccine for multibacillary leprosy ..- Source: s.l; s.n; 1999. 21 p. ilus, graf. Descriptors: VACINA BCG VACINAS BACTERIANAS VACINAS BACTERIANAS ENSAIOS CLINICOS HANSENIASE MYCOBACTERIUM LEPRAE TUBERCULOSE Limits: ANIMAL Location: BR191.1; 07460/s

13 / 20

HANSEN

select to print

Id: 10331 Author: Jayaraman, K. S Title: Charges fly over rival lleprosy vaccines ..- Source: s.l; s.n; 1994. 1 p. ilus. Descriptors: VACINAS BACTERIANAS ENSAIOS CLINICOS INDIA HANSENIASE HANSENIASE MYCOBACTERIUM MYCOBACTERIUM Location: BR191.1; 07182/s

14 / 20

HANSEN

select to print

Id: 10210 Author: Cohen, Jon Title: Vaccines get a new twist ..- Source: s.l; s.n; 1994. 3 p. ilus, tab. Descriptors: ENSAIOS CLINICOS HEPATITE B HERPES GENITAL IMUNOTERAPIA ATIVA LEISHMANIOSE HANSENIASE TUBERCULOSE Location: BR191.1; 06911/s

15 / 20

HANSEN

select to print

Id: 10153 Author: Ebrahim, G. J Title: Elimination of leprosy as a public health problem (Editorial) ..- Source: s.l; s.n; 1997. 2 p. . Descriptors: ENSAIOS CLINICOS CONTROLE DE DOENÇAS TRANSMISSIVEIS SURTOS DE DOENÇAS INCIDENCIA LEPROSTATICOS HANSENIASE HANSENIASE SAUDE MUNDIAL ORGANIZAÇAO MUNDIAL DA SAUDE Location: BR191.1; 07126/s

16 / 20

HANSEN

select to print

Id: 10115 Author: Jain, Sanjiv; Sehgal, Virendra N Title: Multidrug therapeutic challenges in leprosy ..- Source: s.l; s.n; 1997. 4 p. tab. Descriptors: ENSAIOS CLINICOS ESQUEMA DE MEDICAÇAO QUIMIOTERAPIA COMBINADA INDIA LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE HANSENIASE PROGNOSTICO RECIDIVA RESULTADO DE TRATAMENTO Location: BR191.1; 07056/s

17 / 20

HANSEN

select to print

Id: 9915 Author: Pattyn, S. R Title: Future trends in the treatment of leprosy ..- Source: s.l; s.n; 1994. 4 p. tab. Descriptors: HANSENIASE HANSENIASE HANSENIASE LEPROSTATICOS LEPROSTATICOS QUIMIOTERAPIA COMBINADA ESTUDOS LONGITUDINAIS RECIDIVA FATORES DE TEMPO RESULTADO DE TRATAMENTO ENSAIOS CLINICOS Location: BR191.1; 06876/s

18 / 20

HANSEN

select to print

Id: 9377 Author: Deo, M. G Title: Leprosy vaccines (Correspondence) ..- Source: s.l; s.n; 1992. 2 p. . Descriptors: VACINAS BACTERIANAS ENSAIOS CLINICOS ÉTICA MÉDICA HANSENIASE MYCOBACTERIUM LEPRAE Location: BR191.1; 06423/s

19 / 20

HANSEN

select to print

Id: 9345 Author: Arain, Ghazala Moihyuddin Title: BCG vaccination ..- Source: s.l; s.n; 1991. 2 p. . Descriptors: VACINA BCG ENSAIOS CLINICOS HANSENIASE TUBERCULOSE PULMONAR VACINAÇAO Location: BR191.1; 06456/s

20 / 20

HANSEN

select to print

Id: 394 Author: Romero, Arturo; Brenes Ibarra, Abelardo; Fallas, Marcial. Title: Estudio clinico de la lepra lepromatosa en Costa Rica. Source: In: Congreso Internacional de la Lepra, 5.Congreso Internacional de la Lepra, 5/Memoria. Havana, Asociacion Internacional de Lepra, 1948. p.1281-5. Conference: Present in: Congreso Internacional de la Lepra, 5, Havana, 3-11 abr. 1948. Descriptors: HANSENIASE LEPROMATOSA ENSAIOS CLINICOS COSTA RICA Limits: RELATO DE CASO ESTUDO COMPARATIVO Location: BR191.1; WC335.3, C76m

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information